Abstract
Nanotechnology offers many benefits, and here we report an advantage of applying RNA nanotechnology for directional control. The orientation of arrow-shaped RNA was altered to control ligand display on extracellular vesicle membranes for specific cell targeting, or to regulate intracellular trafficking of small interfering RNA (siRNA) or microRNA (miRNA). Placing membrane-anchoring cholesterol at the tail of the arrow results in display of RNA aptamer or folate on the outer surface of the extracellular vesicle. In contrast, placing the cholesterol at the arrowhead results in partial loading of RNA nanoparticles into the extracellular vesicles. Taking advantage of the RNA ligand for specific targeting and extracellular vesicles for efficient membrane fusion, the resulting ligand-displaying extracellular vesicles were capable of specific delivery of siRNA to cells, and efficiently blocked tumour growth in three cancer models. Extracellular vesicles displaying an aptamer that binds to prostate-specific membrane antigen, and loaded with survivin siRNA, inhibited prostate cancer xenograft. The same extracellular vesicle instead displaying epidermal growth-factor receptor aptamer inhibited orthotopic breast cancer models. Likewise, survivin siRNA-loaded and folate-displaying extracellular vesicles inhibited patient-derived colorectal cancer xenograft.
| Original language | English |
|---|---|
| Pages (from-to) | 82-89 |
| Number of pages | 8 |
| Journal | Nature Nanotechnology |
| Volume | 13 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2018 |
Bibliographical note
Publisher Copyright:© 2017 The Author(s).
Funding
We thank H. G. Zhang for his communication during the investigation of the exosome project, and J. Zhang, H. Weiss, D. Wu and D. Gao for assistance with statistical analysis. The research was supported mainly by National Institutes of Health grants UH3TR000875 and U01CA207946 (P. G.), and partially by R01CA186100 (B. G.), R35CA197706 (C.M.C.), P30CA177558 and R01CA195573 (B.M.E.). P.G.’s Sylvan G. Frank Endowed Chair position in Pharmaceutics and Drug Delivery is funded by the CM Chen Foundation, and he is a consultant of Oxford Nanopore, Nanobio Delivery Pharmaceutical Co., Ltd, and the cofounder of P&Z Biological Technology LLC. F.P. now works for Nanobio Delivery Pharmaceutical Co., Ltd. S.W. and F.H. now work for P&Z Biological Technology LLC.
| Funders | Funder number |
|---|---|
| CM Chen Foundation | |
| P&Z Biological Technology LLC | |
| National Institutes of Health (NIH) | P30CA177558, U01CA207946, R01CA195573, UH3TR000875, R01CA186100, R35CA197706 |
| National Institutes of Health (NIH) | |
| National Childhood Cancer Registry – National Cancer Institute | P30CA016058 |
| National Childhood Cancer Registry – National Cancer Institute |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
ASJC Scopus subject areas
- Bioengineering
- Atomic and Molecular Physics, and Optics
- Biomedical Engineering
- General Materials Science
- Condensed Matter Physics
- Electrical and Electronic Engineering
Fingerprint
Dive into the research topics of 'Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver